Trial Profile
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome-Endocrine cardiomyopathy in cushing syndrome: Response to cyclic GMP PDE5 inhibitOrs.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2023
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Cardiomyopathies; Cushing syndrome
- Focus Therapeutic Use
- Acronyms ERGO
- 12 May 2023 Status changed from recruiting to completed.
- 10 Jan 2018 New trial record